AR075605A1 - IMIDAZOLILPIRAZINE DERIVATIVES - Google Patents
IMIDAZOLILPIRAZINE DERIVATIVESInfo
- Publication number
- AR075605A1 AR075605A1 ARP100100547A ARP100100547A AR075605A1 AR 075605 A1 AR075605 A1 AR 075605A1 AR P100100547 A ARP100100547 A AR P100100547A AR P100100547 A ARP100100547 A AR P100100547A AR 075605 A1 AR075605 A1 AR 075605A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- alkylsulfonyl
- alkanoyl
- amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Composicion farmacéutica y usos de los inhibidores de beta-amiloide (Abeta). Reivindicacion 1: Un compuesto caracterizado por la formula (1) o su sal o éster aceptable para uso farmacologico, donde R1 y R2 son iguales o diferentes y cada uno representa un sustituyente seleccionado del siguiente Grupo sustituyente a1; m representa un entero de 0 a 3; n representa un entero de 0 a 2; X1 representa i) un enlace simple, ii) Formula 2 -C::C- o iii) -CRCR3=CR4- (donde R3 y R4 son iguales o diferentes y cada uno representa (1) un átomo de hidrogeno, (2) un grupo alquilo C1-6 o (3) un átomo de halogeno); X2 representa i) un enlace simple, ii) un grupo alquileno C1-6 o iii) -X3- (donde X3 representa -NR5-, -O-, -C(O)-, -S-, -S(O)- o -S(O)2- y R5 representa un átomo de hidrogeno, un grupo alquilo C1-6, cicloalquilo C3-8, alcanoilo C2-6 o alquilsulfonilo C1-6); El anillo A representa i) un grupo heterocíclico aromático de cinco miembros o ii) un grupo heterocíclico aromático de cinco miembros fusionado con un grupo no aromático de 5 a 14 miembros, el cual contiene dos o más átomos de nitrogeno y puede tener 1 a 3 sustituyentes seleccionados del siguiente Grupo Sustituyente b1 (donde el grupo del anillo no aromático puede tener una estructura entrecruzada o un sistema anular espiro) ; y El anillo B representa un anillo aromático cíclico monocíclico o fusionado seleccionado del grupo integrado por las formulas [2] a [19] cada uno de los cuales puede tener 1 a 3 sustituyentes seleccionados del siguiente Grupo Sustituyente c1, Grupo Sustituyente a1: un grupo alquilo C1-6, cicloalquilo C3-8, alquenilo C2-6, alcoxi C1-6, alqueniloxi C2-6, cicloalquiloxi C3-8, amino (donde el grupo amino puede tener un grupo alcanoílo C2-6 o alquilsulfonilo C1-6 o 1 o 2 grupos alquilo C1-6 o grupos cicloalquilo C3-8), un grupo ciano, formilo, un átomo de halogeno, un grupo hidroxilo y un grupo nitro; Grupo Sustituyente b1: un grupo alquilo C1-6 (donde el grupo alquilo puede estar sustituido con 1 a 3 átomos de halogeno), alquenilo C2-6, cicloalquilo C3-8, arilo C6-14, alquil C1-6-arilo C6-14, alcoxi C1-6, alqueniloxi C2-6, cicloalquiloxi C3-8, alcanoilo C2-6, cicloalquilcarbonilo C4-9, aroílo C7-15, alquilsulfonilo C1-6, alquenilsulfonilo C2-6, cicloalquilsulfonilo C3-8, arilsulfonilo C6-14, alquiltio C1-6, alqueniltio C2-6, cicloalquiltio C3-8, aminosulfonilo (donde el grupo aminosulfonilo puede tener 1 a 2 grupos alquilo C1-6, grupos alquenilo C2-6, o grupos cicloalquilo C3-8), amino (donde el grupo amino puede tener un grupo alcanoilo C2-6, un grupo alquilsulfonilo C1-6 o un grupo cicloalquilsulfonilo C3-8 o 1 a 2 grupos alquilo C1-6 o grupos cicloalquilo C3-8), ciano, formilo, un átomo de halogeno, un grupo hidroxilo, nitro, un grupo oxo, un grupo 1-pirrolidinilo, 1-piperidinilo, 1-homopiperidinilo, indolin-1-ilo, 1,2,3, 4-tetrahidroquinolin-1-ilo y un grupo 4-morfolinilo; Grupo Sustituyente c1: i) un grupo amino (donde el grupo amino puede tener un grupo alcanoílo C2-6, alquilsulfonilo C1-6, cicloalquilsulfonilo C3-8, o 1 a 2 grupos alquilo C1-6 o grupos cicloalquilo C3-8), ii) un grupo ciano, iii) un átomo de halogeno, iv) un grupo hidroxilo y v) v)-i) un grupo alquilo C1-6, v)-ii) alquenilo C2-6, v)-iii) alquinilo C2-6, v)-iv) alcoxi C1-6, v)-v) alquiltio C1-6, v)-vi) alquilaminocarbonilo C1-6, v)-vii) alquilsulfonilo C1-6, v)-viii) alquilaminosulfonilo C1-6, v)-ix) alcanoílo C2- 6, v)-x) fenilo, v)-xi) piridilo, v)-xii piridazinilo, v)-xiii) pirimidinilo, v)-xiv) 1-pirrolidinilo, v)-xv) 1-piperidinilo, v)-xvi) 1-homopiperidinilo y v)-xvii) 4-morfolinilo, cada uno de los cuales tiene 1 a 3 sustituyentes seleccionados del grupo integrado por un grupo alquilo C1-6 y un átomo de halogeno.Pharmaceutical composition and uses of beta-amyloid inhibitors (Abeta). Claim 1: A compound characterized by the formula (1) or its salt or ester acceptable for pharmacological use, wherein R1 and R2 are the same or different and each represents a substituent selected from the following Substituent Group a1; m represents an integer from 0 to 3; n represents an integer from 0 to 2; X1 represents i) a simple bond, ii) Formula 2 -C :: C- or iii) -CRCR3 = CR4- (where R3 and R4 are the same or different and each represents (1) a hydrogen atom, (2) a C1-6 alkyl group or (3) a halogen atom); X2 represents i) a single bond, ii) a C1-6 or iii alkylene group -X3- (where X3 represents -NR5-, -O-, -C (O) -, -S-, -S (O) - or -S (O) 2- and R5 represents a hydrogen atom, a C1-6 alkyl, C3-8 cycloalkyl, C2-6 alkanoyl or C1-6 alkylsulfonyl) group; Ring A represents i) a five-membered aromatic heterocyclic group or ii) a five-membered aromatic heterocyclic group fused with a 5 to 14-membered non-aromatic group, which contains two or more nitrogen atoms and may have 1 to 3 substituents selected from the following Substituent Group b1 (where the non-aromatic ring group may have a crosslinked structure or a spiro ring system); and Ring B represents a monocyclic or fused cyclic aromatic ring selected from the group consisting of formulas [2] to [19] each of which may have 1 to 3 substituents selected from the following Substituent Group c1, Substituent Group a1: a group C 1-6 alkyl, C 3-8 cycloalkyl, C 2-6 alkenyl, C 1-6 alkoxy, C 2-6 alkenyloxy, C 3-8 cycloalkyloxy, amino (wherein the amino group may have a C 2-6 alkanoyl group or C 1-6 alkylsulfonyl group or 1 or 2 C1-6 alkyl groups or C3-8 cycloalkyl groups), a cyano group, formyl, a halogen atom, a hydroxyl group and a nitro group; Substituent Group b1: a C1-6 alkyl group (where the alkyl group may be substituted with 1 to 3 halogen atoms), C2-6 alkenyl, C3-8 cycloalkyl, C6-14 aryl, C1-6 alkyl-C6- aryl 14, C1-6 alkoxy, C2-6 alkenyloxy, C3-8 cycloalkyloxy, C2-6 alkanoyl, C4-9 cycloalkylcarbonyl, C7-15 aroyl, C1-6 alkylsulfonyl, C2-6 alkenylsulfonyl, C3-8 cycloalkylsulfonyl, C6- arylsulfonyl 14, C1-6 alkylthio, C2-6 alkenylthio, C3-8 cycloalkylthio, aminosulfonyl (wherein the aminosulfonyl group may have 1 to 2 C1-6 alkyl groups, C2-6 alkenyl groups, or C3-8 cycloalkyl groups), amino ( wherein the amino group may have a C2-6 alkanoyl group, a C1-6 alkylsulfonyl group or a C3-8 cycloalkylsulfonyl group or 1 to 2 C1-6 alkyl groups or C3-8 cycloalkyl groups), cyano, formyl, an atom of halogen, a hydroxyl group, nitro, an oxo group, a 1-pyrrolidinyl, 1-piperidinyl, 1-homopiperidinyl, indolin-1-yl, 1,2,3, 4-tetrahydroquinolin-1-yl group and a group 4- morpholinyl; Substituent group c1: i) an amino group (where the amino group may have a C2-6 alkanoyl group, C1-6 alkylsulfonyl, C3-8 cycloalkylsulfonyl, or 1 to 2 C1-6 alkyl groups or C3-8 cycloalkyl groups), ii) a cyano group, iii) a halogen atom, iv) a hydroxyl group and v) v) -i) a C1-6 alkyl group, v) -ii) C2-6 alkenyl, v) -iii) C2- alkynyl 6, v) -iv) C1-6 alkoxy, v) -v) C1-6 alkylthio, v) -vi) C1-6 alkylaminocarbonyl, v) -vii) C1-6 alkylsulfonyl, v) -viii) C1- alkylaminosulfonyl 6, v) -ix) C2-6 alkanoyl, v) -x) phenyl, v) -xy) pyridyl, v) -xii pyridazinyl, v) -xiii) pyrimidinyl, v) -xiv) 1-pyrrolidinyl, v) -xv) 1-piperidinyl, v) -xvi) 1-homopiperidinyl and v) -xvii) 4-morpholinyl, each of which has 1 to 3 substituents selected from the group consisting of a C1-6 alkyl group and a halogen atom .
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15565709P | 2009-02-26 | 2009-02-26 | |
JP2009043300A JP2012051806A (en) | 2009-02-26 | 2009-02-26 | Imidazolylpyrazine derivative |
Publications (1)
Publication Number | Publication Date |
---|---|
AR075605A1 true AR075605A1 (en) | 2011-04-20 |
Family
ID=42184107
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100100547A AR075605A1 (en) | 2009-02-26 | 2010-02-25 | IMIDAZOLILPIRAZINE DERIVATIVES |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP2012051806A (en) |
AR (1) | AR075605A1 (en) |
TW (1) | TW201031662A (en) |
WO (1) | WO2010098495A1 (en) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10164139A1 (en) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-heteroaryl carboxamides |
AR068121A1 (en) | 2007-08-31 | 2009-11-04 | Eisai R&D Man Co Ltd | MULTICICLICAL COMPOUNDS TO TREAT NEURODEGENERATIVE DISEASES |
PA8854101A1 (en) | 2008-12-18 | 2010-07-27 | Ortho Mcneil Janssen Pharm | IMIDAZOL BICYCLIC DERIVATIVES REPLACED AS MODULATORS OF GAMMA SECRETASA |
JP5576403B2 (en) | 2009-02-06 | 2014-08-20 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | Novel substituted bicyclic heterocyclic compounds as γ-secreting enzyme regulators |
TWI461425B (en) | 2009-02-19 | 2014-11-21 | Janssen Pharmaceuticals Inc | Novel substituted benzoxazole, benzimidazole, oxazolopyridine and imidazopyridine derivatives as gamma secretase modulators |
KR20110122746A (en) | 2009-02-26 | 2011-11-10 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors |
BRPI1007883A2 (en) | 2009-02-26 | 2016-02-23 | Eisai R&D Man Co Ltd | salt and crystal. |
CN102439005B (en) | 2009-05-07 | 2015-07-22 | 杨森制药公司 | Novel substituted indazole and aza-indazole derivatives as gamma secretase modulators |
BR112012000915A2 (en) | 2009-07-15 | 2019-09-24 | Janssen Pharmaceuticals Inc | substituted triazole and imidazole derivatives as gamma secretase modulators. |
US9145399B2 (en) | 2010-01-15 | 2015-09-29 | Janssen Pharmaceuticals, Inc. | Substituted bicyclic triazole derivatives as gamma secretase modulators |
DK3029039T3 (en) | 2010-05-17 | 2017-12-04 | Forum Pharmaceuticals Inc | PHARMACEUTICAL FORMS CONTAINING CRYSTALLINIC FORMS OF (R) -7-CHLOR-N- (QUINUCLIDIN-3-YL) BENZO (B) THIOPHEN-2-CARBOXAMIDE HYDROCHLORIDE MONOHYDRATE |
UY33551A (en) | 2010-08-10 | 2012-03-30 | Takeda Pharmaceutical | HETEROCYCLIC COMPOUND AND ITS USE |
CA2809779A1 (en) | 2010-09-02 | 2012-03-08 | Takeda Pharmaceutical Company Limited | Fused triazoles for the treatment or prophylaxis of mild cognitive impairment |
AU2012230348A1 (en) | 2011-03-24 | 2013-08-29 | Cellzome Limited | Novel substituted triazolyl piperazine and triazolyl piperidine derivatives as gamma secretase modulators |
ES2602794T3 (en) | 2011-03-31 | 2017-02-22 | Pfizer Inc | Novel bicyclic pyridinones |
KR101913135B1 (en) * | 2011-07-15 | 2018-10-30 | 얀센 파마슈티칼즈, 인코포레이티드 | Novel substituted indole derivatives as gamma secretase modulators |
WO2013169646A1 (en) | 2012-05-08 | 2013-11-14 | Envivo Pharmaceuticals, Inc. | Methods of maintaining, treating or improving cognitive function |
NZ702611A (en) | 2012-05-16 | 2016-10-28 | Cellzome Ltd | Substituted 3, 4 - dihydro - 2h - pyrido [1, 2 -a] pyrazine - 1, 6 - dione derivatives useful for the treatment of (inter alia) alzheimer’s disease |
EP2687528A1 (en) * | 2012-07-17 | 2014-01-22 | Ares Trading S.A. | Fused triazole derivatives as gamma secretase modulators |
UA110688C2 (en) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Bicyclic pirydynony |
EP2953949B1 (en) | 2012-12-20 | 2016-09-28 | Janssen Pharmaceutica NV | Novel tricyclic 3,4-dihydro-2h-pyrido[1,2-a]pyrazine-1,6-dione derivatives as gamma secretase modulators |
JP6283691B2 (en) | 2013-01-17 | 2018-02-21 | ヤンセン ファーマシューティカ エヌ.ベー. | Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators |
US10562897B2 (en) | 2014-01-16 | 2020-02-18 | Janssen Pharmaceutica Nv | Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators |
EA033423B1 (en) | 2015-02-03 | 2019-10-31 | Pfizer | Cyclopropabenzofuranyl pyridopyrazinediones |
CN107118173B (en) * | 2017-07-12 | 2019-10-29 | 阿里生物新材料(常州)有限公司 | A kind of cycloheptatriene and oxazine compound and preparation method thereof |
KR20200094734A (en) | 2017-09-22 | 2020-08-07 | 주빌런트 에피파드 엘엘씨 | Heterocyclic compounds as PAD inhibitors |
AU2018348930A1 (en) * | 2017-10-11 | 2020-03-26 | F. Hoffmann-La Roche Ag | Bicyclic compounds for use as RIP 1 kinase inhibitors |
MX2020003341A (en) | 2017-10-18 | 2020-09-17 | Jubilant Epipad LLC | Imidazo-pyridine compounds as pad inhibitors. |
JP7279057B6 (en) | 2017-11-06 | 2024-02-15 | ジュビラント プローデル エルエルシー | Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation |
EP3704120B1 (en) | 2017-11-24 | 2024-03-06 | Jubilant Episcribe LLC | Heterocyclic compounds as prmt5 inhibitors |
MX2020009517A (en) | 2018-03-13 | 2021-01-20 | Jubilant Prodel LLC | Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation. |
CN111205345A (en) * | 2020-01-19 | 2020-05-29 | 四川澄华生物科技有限公司 | Preparation method of obeticholic acid |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7244739B2 (en) | 2003-05-14 | 2007-07-17 | Torreypines Therapeutics, Inc. | Compounds and uses thereof in modulating amyloid beta |
DE102006013698A1 (en) | 2006-03-24 | 2007-09-27 | Robert Bosch Gmbh | Gas sensor e.g. ammonia sensor, for e.g. diesel combustion engine, has measuring electrode covered with catalyst e.g. selective catalytic-reduction catalyst, for chemical reaction of nitrogen oxides |
JP2009184924A (en) | 2006-05-31 | 2009-08-20 | Eisai R & D Management Co Ltd | Compound for biological reagent |
-
2009
- 2009-02-26 JP JP2009043300A patent/JP2012051806A/en active Pending
-
2010
- 2010-01-29 TW TW099102604A patent/TW201031662A/en unknown
- 2010-02-24 WO PCT/JP2010/053378 patent/WO2010098495A1/en active Application Filing
- 2010-02-25 AR ARP100100547A patent/AR075605A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
TW201031662A (en) | 2010-09-01 |
JP2012051806A (en) | 2012-03-15 |
WO2010098495A1 (en) | 2010-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR075605A1 (en) | IMIDAZOLILPIRAZINE DERIVATIVES | |
AR075607A1 (en) | ARIL IMIDAZOL COMPOUNDS | |
ES2666870T3 (en) | Dysiropyrrolidine derivative | |
AR075606A1 (en) | FUSIONED HETEROCICLIC COMPOUND CONTAINING NITROGEN, A MEDICINE THAT UNDERSTANDS IT AND ITS USE IN THE TREATMENT OF DISEASES MEDIATED BY THE INHIBITION OF ABETA PRODUCTION. | |
AR052943A1 (en) | DERIVATIVES OF 2- (4-OXO-4H-QUINAZOLIN-3-IL) ACETAMIDE | |
AR080596A1 (en) | RENTAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS | |
ES2620668T3 (en) | Spirocyclic amido and sulfonamide derivatives | |
AR087328A1 (en) | IMIDAZO DERIVATIVES [1,2-B] PIRIDAZINE AND IMIDAZO [4,5-B] PIRIDINA AS JAK INHIBITORS | |
AR100886A1 (en) | 3-AMINO-1,5,6,7-TETRAHIDRO-4H-INDOL-4-ONAS | |
AR070995A1 (en) | POLISUSTITUTED DERIVATIVES OF 6-HETEROARIL-IMIDAZO [1,2-A] PIRIDINA, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCESS OF THE SAME, INTERMEDIARIES OF SYNTHESIS AND USE OF THE SAME IN THE TREATMENT OR PREVENTION OF NURSING -1, SUCH AS ENFE | |
AR078786A1 (en) | CHROMENONE DERIVATIVES | |
AR088029A1 (en) | SUBSTITUTED PYRIMIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE OF THE SAME FOR THE TREATMENT OF PAIN, CEREBROVASCULAR ACCIDENTS, EPILEPSY AND OTHER DISEASES OF THE CENTRAL NERVOUS SYSTEM | |
AR058198A1 (en) | MORPHOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS | |
AR090572A1 (en) | TIENOPIRIMIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES | |
AR056511A1 (en) | DERIVATIVES OF 2-AMINOPIRIMIDINES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF DISEASES MEDIATED BY THE HISTAMINE RECEIVER H4 | |
AR086546A1 (en) | DERIVATIVES OF 7H-PURIN-8 (9H) -ONA AS JAK INHIBITORS | |
PE20181024A1 (en) | DERIVATIVES OF CYCLOHEXANE SUBSTITUTED WITH AMIDO | |
AR040048A1 (en) | DERIVATIVES OF 1- (AMINOALQUIL) -3-SULFONYLINDOL AND INDAZOL AS LIGANDS OF 5-HYDROXYTHYRIPTAMINE-6 | |
AR064619A1 (en) | DERIVATIVES OF AMINO-IMIDAZOPIRIDINAS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USES OF THE SAME AS ANTITUMORAL AGENTS. | |
AR089568A1 (en) | HETEROCICLICAL COMPOUNDS AND THEIR METHODS OF USE | |
NI200900037A (en) | DERIVATIVES OF 2-ARIL-6-PHENYL-IMIDAZO [1,2-ALPHA] PYRIDINES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS. | |
AR085615A1 (en) | USEFUL FLUOROPIRIDINONE DERIVATIVES AS ANTIBACTERIAL AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
AR079553A1 (en) | DERIVATIVES OF DIAZA-ESPIRO- [5,5] -UNDECANOS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME IN THE TREATMENT OF CNS DISORDERS, SUCH AS DISORDERS OF THE SOUND AND DEPENDENCY, AMONG OTHERS. | |
AR073498A1 (en) | DERIVATIVES OF TIENO [2-3-D] PIRIMIDIN | |
AR087841A1 (en) | TETRAHYDROTRIAZOLOPIRIMIDINE DERIVATIVES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |